Table 1

Clinical characteristics of obese hypertensive and normotensive patients
Compared groups and clinical data Group A Group B Statistical significance p
n = 54 n = 11
n (%) (%)
Males/females 20 (37.0%)/34 (63.0%) 5 (45.5%)/6 (54.5) NS
Age (years) 57.9 ± 11.0 46.1 ± 10.8 p = 0.001
Ischemic heart disease 18 (33.3%) 2 (18.2%) NS
Myocardial infarct 7 (13.0%) 1 (9.1%) NS
Cardiac failure 22 (40.7%) 3 (27.3%) NS
IFG/IGT 34 (63.0%) 4 (36.4%) NS
CKD 14 (25.9%) 1 (9.1%) NS
Stroke 3 (5.6%) 0 NS
Cerebral arteries failure 3 (5.6%) 0 NS
Hyperuricemia 24 (44.4%) 2 (18.2%) NS
Dyslipidaemia 52 (96.3%) 9 (81.8%) NS
Tobacco smoking 5 (9.3%) 0 NS
ACEI 44 (81.5%) 1 (9.1%) p < 0.0001
ARB 17 (31.5%) 0 p = 0.05
Diuretics 35 (64.8%) 1 (9.1%) p < 0.01
CCA 19 (35.2%) 0 p < 0.05
BB 23 (40.7%) 2 (18.2%) NS
Spironolactone 17 (31.5%) 1 (9.1%) NS
ARA 7 (13.0%) 0 NS
ASA 15 (27.8%) 1 (9.1%) NS
Hypolipemic treatmenta 31 (57.4%) 4 (36.4%) NS

IFG – impaired fasting glucose. IGT – impaired glucose tolerance. CKD – chronic kidney disease. COPD – chronic pulmonary obstructive disease. ACEI – angiotensin-converting enzyme inhibitor. ARB – angiotensin II receptor antagonist. CCA – calcium channel antagonist. BB – β-adrenergic receptor blocker. ARA – α1-adrenergic receptor antagonist. ASA – acetylsalicylic acid. NS – not significant. a – statins and/or fibrates.

Stępień et al.

Stępień et al. Lipids in Health and Disease 2014 13:29   doi:10.1186/1476-511X-13-29

Open Data